Immunovant Inc (IMVT) - News Archive

Revolutionizing Autoimmune Disease Treatment: Immunovant s Strategic $450 Million Private PlacementIn a significant financial maneuver, Immunovant, Inc. (Nasdaq: IMVT), a pioneering clinical-stage immunology company, ha...

Immunovant, Inc. (Nasdaq: IMVT) is a clinical-stage immunology company that strives to improve the lives of individuals suffering from autoimmune diseases. In their recent corporate updates and financial results for the...

NEW YORK, Dec. 20, 2023 - Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company committed to enhancing the quality of life for individuals with autoimmune diseases, has made a groundbreaking breakthrough...

Immunovant s IMVT-1402 Demonstrates Promising Results as a Best-in-Class FcRn InhibitorNEW YORK, Nov. 28, 2023 - Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company committed to improving the lives of i...